Evidence Hub

Glycoprotein IIb/IIIa platelet receptor inhibitors: a new dimension in cardiology

Tan HC

Annals of the Academy of Medicine, Singapore, 1997

Abstract

Platelets play a key role in the pathogenesis of atherosclerosis, acute coronary syndromes and ischaemic complications following percutaneous coronary intervention. More recently, the platelet glycoprotein (GP) IIb/IIIa receptor has been identified as the pivotal mediator of platelet aggregation, leading to thrombus formation. This has led to the emergence of a novel class of potent antiplatelet agent, the GP IIb/IIIa receptor antagonists. These agents show great promise in reducing ischaemic complications of coronary angioplasty and acute coronary syndromes. This review summarizes the current state of knowledge of the biology of GP IIb/IIIa receptor, the different classes of GP IIb/IIIa receptor antagonists, the results of the various trials, and their impact on current clinical practice.

How strong is the evidence?

Evidence Hub reads this as a review, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free